Related Experiment Videos
Idiopathic Intracranial Hypertension
Robert K. Shin1, Laura J. Balcer
1*Department of Neurology, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. lbalcer@mail.med.upenn.edu
Current Treatment Options in Neurology
|May 31, 2002
Summary
Idiopathic intracranial hypertension (IIH), or pseudotumor cerebri, is a vision-threatening condition. Management includes weight loss, medication review, and treatments like acetazolamide, surgery, or bariatric procedures for obese patients.
Area of Science:
- Neurology
- Ophthalmology
Background:
- Idiopathic intracranial hypertension (IIH), also known as pseudotumor cerebri, poses a significant risk to vision.
- Close monitoring of visual acuity, visual fields, and fundus appearance is crucial for all IIH patients.
Purpose of the Study:
- To outline current management strategies for idiopathic intracranial hypertension.
- To emphasize the importance of multidisciplinary care and tailored treatment approaches.
Main Methods:
- Review of existing literature and clinical guidelines for IIH management.
- Discussion of pharmacological, surgical, and lifestyle interventions.
Main Results:
- Weight loss is recommended for obese patients with IIH.
- Medications potentially causing or worsening IIH should be discontinued.
- Acetazolamide is a first-line treatment for symptomatic patients or those with vision loss; furosemide may be a second-line option.
- Surgical interventions like optic nerve sheath fenestration or lumboperitoneal shunting are considered for progressive vision loss or refractory symptoms.
- Bariatric surgery offers a long-term solution for severely obese patients but is not for acute management.
Conclusions:
- Effective management of IIH requires a comprehensive approach, including lifestyle modifications, pharmacotherapy, and potentially surgical intervention.
- Treatment decisions should be individualized based on symptom severity, vision status, and patient-specific factors.
- Special considerations are necessary for pediatric and pregnant populations with IIH.